KeyBanc last night upgraded Exagen (XGN) to Overweight from Sector Weight with a $12 price target The firm sees higher revenue visibility due to the company’s improved pricing, salesforce additions, and new payers like Tricare. Exagen is a leader in autoimmune diagnostics and its revenue guidance implies growth of 17%-25% in 2025, the analyst tells investors in a research note. KeyBanc believes the company is working to expand its leading market position in novel connective tissue diagnosis with new biomarkers in early 2026 to increase the “moat” around its core test.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XGN:
- Exagen Inc. Reports Record Q2 2025 Revenue
- Exagen’s Promising Financial Trajectory and Raised Price Target Amid Strong Performance and Strategic Growth Initiatives
- Exagen upgraded to Overweight from Sector Weight at KeyBanc
- Exagen reports Q2 EPS (21c), consensus (15c)
- Exagen sees FY25 revenue $65M-$70M, consensus $65.87M